SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in central ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA ...

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

A multidisciplinary team of University of Cincinnati Cancer Center researchers has received a $40,000 Ride Cincinnati grant to study a delayed release preparation, or wafer, of an immunostimulatory ...

In regenerative medicine, macrophages and stem cells play pivotal roles in repairing central nervous system (CNS) injuries. These cells are instrumental due ...

Recently, a study published in Research (November 24) successfully developed an innovative nanotherapy to combat carbapenem-resistant central nervous ...

Cycle Group Holdings Limited has completed its acquisition of Applied Therapeutics Inc., a clinical-stage biopharmaceutical ...

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies ...

- Portfolio available in 60+ markets and deepens our CNS footprint in Brazil, South Africa, France and Italy BASILDON, England--(BUSINESS WIRE)--PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ...

Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...